These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 18986646

  • 1. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
    Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH.
    Biol Psychiatry; 2009 Mar 15; 65(6):510-7. PubMed ID: 18986646
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
    Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD.
    Psychopharmacology (Berl); 2006 Dec 15; 189(2):259-66. PubMed ID: 17058105
    [Abstract] [Full Text] [Related]

  • 3. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.
    J Clin Psychiatry; 2004 Dec 15; 65 Suppl 18():47-56. PubMed ID: 15600384
    [Abstract] [Full Text] [Related]

  • 4. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.
    J Clin Psychiatry; 2008 Jul 15; 69(7):1046-56. PubMed ID: 18605811
    [Abstract] [Full Text] [Related]

  • 5. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J.
    J Clin Psychopharmacol; 2008 Dec 15; 28(6):601-7. PubMed ID: 19011427
    [Abstract] [Full Text] [Related]

  • 6. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
    Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A.
    J Clin Psychiatry; 2009 Apr 15; 70(4):572-81. PubMed ID: 19323965
    [Abstract] [Full Text] [Related]

  • 7. Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India.
    Jindal KC, Singh GP, Munjal V.
    Int J Psychiatry Clin Pract; 2013 Feb 15; 17(1):21-9. PubMed ID: 22339214
    [Abstract] [Full Text] [Related]

  • 8. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH.
    Am J Psychiatry; 2008 Nov 15; 165(11):1432-41. PubMed ID: 18765484
    [Abstract] [Full Text] [Related]

  • 9. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.
    Eur Psychiatry; 2007 Oct 15; 22(7):433-43. PubMed ID: 17555947
    [Abstract] [Full Text] [Related]

  • 10. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
    Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R, Aripiprazole Study Group.
    J Clin Psychiatry; 2007 Feb 15; 68(2):213-23. PubMed ID: 17335319
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
    Ascher-Svanum H, Stensland MD, Peng X, Faries DE, Stauffer VL, Osuntokun OO, Kane JM.
    Curr Med Res Opin; 2011 Jan 15; 27(1):115-22. PubMed ID: 21110749
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN.
    J Psychiatr Res; 2007 Dec 15; 41(11):895-905. PubMed ID: 17631314
    [Abstract] [Full Text] [Related]

  • 13. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ, Ree SC, Huang YS, Hsiao CC, Chen CK.
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan 10; 40():260-6. PubMed ID: 23085073
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.
    J Clin Psychiatry; 2002 Sep 10; 63(9):763-71. PubMed ID: 12363115
    [Abstract] [Full Text] [Related]

  • 15. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.
    Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester-Blokland E, McQuade RD, Crandall DT, Carson WH, Marcus RN, L'italien G.
    Schizophr Res; 2008 Dec 10; 106(2-3):300-7. PubMed ID: 18973991
    [Abstract] [Full Text] [Related]

  • 16. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.
    J Affect Disord; 2009 May 10; 115(1-2):18-26. PubMed ID: 19230981
    [Abstract] [Full Text] [Related]

  • 17. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.
    Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T, Aripiprazole Study Group.
    J Psychopharmacol; 2006 Jul 10; 20(4):536-46. PubMed ID: 16401666
    [Abstract] [Full Text] [Related]

  • 18. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, Cho SJ, APLUS study group.
    Psychiatry Clin Neurosci; 2009 Feb 10; 63(1):73-81. PubMed ID: 19154213
    [Abstract] [Full Text] [Related]

  • 19. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
    Adams DH, Kinon BJ, Baygani S, Millen BA, Velona I, Kollack-Walker S, Walling DP.
    BMC Psychiatry; 2013 May 22; 13():143. PubMed ID: 23694720
    [Abstract] [Full Text] [Related]

  • 20. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO.
    Am J Psychiatry; 2004 Oct 22; 161(10):1837-47. PubMed ID: 15465981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.